RemeGen Co. Ltd. Class A
688331
Classement en actions
#2476
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Prix de l'action
$14.07
Capitalisation boursière
$7.88B
Changement (1 jour)
-2.90%
Changement (1 an)
2.98%
Pays
CN
Échange RemeGen Co. Ltd. Class A (688331)
Catégorie
Healthcare
EPS pour RemeGen Co. Ltd. Class A (688331)
EPS au June 2026 TTM : $1.51
Selon les derniers rapports financiers et le cours de l'action de RemeGen Co. Ltd. Class A, l’EPS actuel de la société (TTM) est de $1.51. À la fin de 2023, la société avait un EPS de $-0.40 une augmentation par rapport à celui de 2022, qui était de $-0.27.
Historique de l'EPS de RemeGen Co. Ltd. Class A de 2018 à 2026
EPS à la fin de chaque année
| Année | EPS | Changez |
|---|---|---|
| 2026 (TTM) | $1.51 | -506.95% |
| 2024 | $-0.37 | -5.46% |
| 2023 | $-0.40 | 45.17% |
| 2022 | $-0.27 | -403.79% |
| 2021 | $0.09 | -134.26% |
| 2020 | $-0.26 | 102.63% |
| 2019 | $-0.13 | 58.72% |
| 2018 | $-0.08 | 0.00% |
EPS pour des entreprises ou concurrents similaires
| Entreprise | EPS | Différence d’EPS | Pays |
|---|---|---|---|
| $17.32 | 1,050.30% |
US
|
|
| $-7.98 | -629.99% |
US
|
|
| $-5.29 | -451.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,742.33% |
NL
|
